Morepen Labs QIP Fund Utilization: Rs. 167.65 Cr Utilized, Rs. 21.43 Cr Unutilized as of Dec 31, 2025
Morepen Laboratories Limited utilized ₹167.65 crore of its ₹200 crore QIP issue proceeds by December 31, 2025. ₹101.36 crore was spent on manufacturing unit expansion, with ₹21.43 crore remaining unutilized. Working capital funding of ₹66.29 crore is fully utilized. A GST refund notice of ₹117.94 crore is under a court stay.
This report is a regulatory filing regarding the utilization of QIP funds. While it details fund deployment and unutilized amounts, it does not contain new financial results or material business developments that would significantly impact the company's stock price in the short term. The ongoing legal matter regarding GST refund could have future implications.
The report provides a routine update on fund utilization with no significant positive or negative financial performance indicators mentioned. However, the mention of declining profitability and a pending GST refund case introduces a neutral to slightly negative undertone.
Morepen Laboratories Limited has submitted its Monitoring Agency Report for the quarter ended December 31, 2025, concerning the utilization of proceeds from its Qualified Institutions Placement (QIP) issue. The company had raised ₹200 crore through this issue, which occurred between August 1 and August 5, 2024.
As of December 31, 2025, a total of ₹167.65 crore from the QIP proceeds has been utilized. The original cost for the modernization and expansion of manufacturing units in Baddi and Masulkhana was ₹122.79 crore, with ₹101.36 crore utilized as of the reporting date, leaving ₹21.43 crore unutilized for this purpose. The funding for working capital requirements, initially planned at ₹64.36 crore, saw a revised cost of ₹66.29 crore, and this amount has been fully utilized.
During the quarter, ₹13.59 crore was expended on modernization and expansion activities. While ₹9.91 crore was directly disbursed from the monitoring account, ₹3.68 crore was transferred to various current accounts for local disbursements. The report notes that the commingling of funds has restricted the direct ascertainment of end-use, leading the agency to rely on management representations and the Chartered Accountant's certificate.
The unutilized proceeds of ₹21.43 crore have been temporarily invested in money market mutual funds, yielding a return of approximately 2.00%. The company has received a stay from the High Court of Himachal Pradesh regarding a show cause notice for an alleged erroneous GST refund of ₹117.94 crore for FY2021 to FY2024, though the matter remains sub judice.
The report also highlights a consistent decline in profitability over the past four quarters due to margin compression in the API segment. The timeline for utilizing ₹88.83 crore for modernization and expansion, originally set for FY25, has been extended to March 31, 2026, through a resolution passed by the QIP committee.
What to do with a filing like this
Morepen Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under other regulatory filings. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Morepen Laboratories Limited. Read the original for the full detail.